Massachusetts Alzheimer's Disease Research Center
马萨诸塞州阿尔茨海默病研究中心
基本信息
- 批准号:10378606
- 负责人:
- 金额:$ 330.67万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-04-15 至 2024-03-31
- 项目状态:已结题
- 来源:
- 关键词:Alzheimer&aposs DiseaseAmyloid beta-ProteinAuthorization documentationAutopsyBasic ScienceBehavioralBiological AssayBiological MarkersBloodBlood VesselsCerebrospinal FluidClinicalClinical DataClinical ResearchClinical SciencesClinical TrialsClinical Trials DesignCognitiveCollaborationsCommunitiesDataData LinkagesData SetDementiaDevelopmentDiagnosisDiagnostic ServicesDiseaseEducationEnvironmentEventFacultyFaculty RecruitmentFertilizationFrontotemporal DementiaFunctional disorderFutureGeneral HospitalsGoalsHeterogeneityImageImaging TechniquesImpairmentIndividualInfrastructureInstitutionKnowledgeLaboratoriesLeadershipLearningLesionLewy Body DiseaseLinkMRI ScansMarshalMassachusettsMeasuresMentorsMethodsMissionMolecular ProfilingNatural ImmunityNerve DegenerationNeurofibrillary TanglesNeuropsychologyParticipantPathologyPatientsPhenotypePlasmaPlayPopulation HeterogeneityPositron-Emission TomographyProcessPrognosisResearchResearch MethodologyResearch PersonnelResearch SupportResourcesRoleSamplingScienceScientistStatistical Data InterpretationStructureTechniquesTechnologyTestingTherapeutic TrialsTrainingTraining ProgramsUpdateWorkbasebiomarker validationclinical biomarkersclinical centerclinical phenotypecohortcommunity settingdigitaldisease heterogeneityeducation researchfollow-upfrontotemporal degenerationimaging biomarkerimaging studyinduced pluripotent stem cellinflammatory markerinter-individual variationmedical schoolsmild cognitive impairmentmultidisciplinaryneuroimagingneuropathologynew technologynext generationoutreachpostersprogramsracial and ethnicrecruitresiliencesymposiumtargeted biomarkertau Proteinstherapeutic evaluationtherapeutic targettoolvalidation studies
项目摘要
OVERVIEW: Massachusetts Alzheimer’s Disease Research Center (MADRC)
The MADRC is an interdisciplinary Center at Massachusetts General Hospital, Harvard Medical School, with
two major strategic goals: 1) to understand the underpinnings of heterogeneity of Alzheimer’s disease and
Alzheimer’s Disease Related Disorders, and 2) to develop techniques, strategies, and technologies to
accelerate a cure. To approach these goals, we propose 7 Cores (Administrative, Clinical, Biomarker,
Imaging, Neuropathology, Data, and Outreach). We will use advanced Imaging, Biomarker, and analytic
approaches to study our Research Cohort, which we view as a state of the art clinical phenotyping laboratory.
Autopsy follow up for validation of biomarkers and imaging, and therapeutic targets, is essential. We plan to
study a diverse population, both in the sense of various pathophysiologies, and also with varying racial and
ethnic backgrounds, and rely on a vigorous ORE core both to fulfill our own recruitment needs and to support
clinical trials and other affiliated programs.
We have refocused our Center’s activities by remodeling the Research Cohort to include subjects who are
cognitively normal, have mild cognitive impairment, or dementia, targeting diverse causes of dementia
including Alzheimer’s disease and related disorders (Frontotemporal dementia, Lewy Body Disease, and
vascular lesions). We postulate that heterogeneity of progression, even among individuals with the same
“disease”, reflects underlying differences that can be uncovered, and that doing so will enhance clinical trial
design by parsing variability from the very large, long cohort trials now in common use.
Each Core is challenged to develop tools to help accelerate a cure – from intermediate imaging/biomarker
targets that may help with diagnosis (a patient’s state) or prognosis (a patient’s fate), to performing autopsies
to validate those targets. We will develop markers of inflammation and neurodegeneration, believing that
innate immunity and resilience play a role in addition to tangles and plaques. Development of statistical and
data methods are critical for anlaysis. These tools will allow us to test hypotheses about faster or slower rates
of progression in a deeply phenotyped cohort.
A final goal, central to our mission, is to build the future by training the next generation of scientists, which we
propose to do under the framework of the Research Education Component. Together, we hope to make a
difference in these devastating diseases.
概述:马萨诸塞州阿尔茨海默病研究中心(MADRC)
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BRADLEY T. HYMAN其他文献
BRADLEY T. HYMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BRADLEY T. HYMAN', 18)}}的其他基金
Discovery and development of apoE4 correctors for the treatment of Alzheimer's disease
发现和开发用于治疗阿尔茨海默病的 apoE4 校正剂
- 批准号:
10901029 - 财政年份:2023
- 资助金额:
$ 330.67万 - 项目类别:
MGH Diseases of Aging Pathway Via Stimulating Access to Research in Residency (MGH DAP StARR)
通过刺激住院医师研究参与 MGH 衰老途径疾病 (MGH DAP StARR)
- 批准号:
10592226 - 财政年份:2023
- 资助金额:
$ 330.67万 - 项目类别:
Multi-omic Brain Cell Atlas of Alzheimer's Disease Progression
阿尔茨海默病进展的多组学脑细胞图谱
- 批准号:
10461533 - 财政年份:2021
- 资助金额:
$ 330.67万 - 项目类别:
LRP1-tau interactions and Alzheimer Disease
LRP1-tau 相互作用与阿尔茨海默病
- 批准号:
10274154 - 财政年份:2021
- 资助金额:
$ 330.67万 - 项目类别:
Massachusetts Alzheimer's Disease Research Center
马萨诸塞州阿尔茨海默病研究中心
- 批准号:
10332246 - 财政年份:2019
- 资助金额:
$ 330.67万 - 项目类别:
Massachusetts Alzheimer's Disease Research Center
马萨诸塞州阿尔茨海默病研究中心
- 批准号:
9914193 - 财政年份:2019
- 资助金额:
$ 330.67万 - 项目类别:
Massachusetts Alzheimer's Disease Research Center
马萨诸塞州阿尔茨海默病研究中心
- 批准号:
10620661 - 财政年份:2019
- 资助金额:
$ 330.67万 - 项目类别:
Massachusetts Alzheimer's Disease Research Center P30 Diversity Supplement Gaona
马萨诸塞州阿尔茨海默病研究中心 P30 多样性补充剂高纳
- 批准号:
10522320 - 财政年份:2019
- 资助金额:
$ 330.67万 - 项目类别:
Massachusetts Alzheimer's Disease Research Center
马萨诸塞州阿尔茨海默病研究中心
- 批准号:
10511260 - 财政年份:2019
- 资助金额:
$ 330.67万 - 项目类别:
相似国自然基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
- 批准号:81000622
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
- 批准号:31060293
- 批准年份:2010
- 资助金额:26.0 万元
- 项目类别:地区科学基金项目
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
- 批准号:30960334
- 批准年份:2009
- 资助金额:22.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Pathophysiological mechanisms of hypoperfusion in mouse models of Alzheimer?s disease and small vessel disease
阿尔茨海默病和小血管疾病小鼠模型低灌注的病理生理机制
- 批准号:
10657993 - 财政年份:2023
- 资助金额:
$ 330.67万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10381163 - 财政年份:2022
- 资助金额:
$ 330.67万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10531959 - 财政年份:2022
- 资助金额:
$ 330.67万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10700991 - 财政年份:2022
- 资助金额:
$ 330.67万 - 项目类别:
Interneurons as early drivers of Huntington´s disease progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10518582 - 财政年份:2022
- 资助金额:
$ 330.67万 - 项目类别:
Interneurons as Early Drivers of Huntington´s Disease Progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10672973 - 财政年份:2022
- 资助金额:
$ 330.67万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10585925 - 财政年份:2022
- 资助金额:
$ 330.67万 - 项目类别:
Oligodendrocyte heterogeneity in Alzheimer' s disease
阿尔茨海默病中的少突胶质细胞异质性
- 批准号:
10180000 - 财政年份:2021
- 资助金额:
$ 330.67万 - 项目类别:
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik study
基于人群的纵向队列研究中阿尔茨海默病的血清蛋白质组分析 - AGES 雷克雅未克研究
- 批准号:
10049426 - 财政年份:2021
- 资助金额:
$ 330.67万 - 项目类别:
Repurposing drugs for Alzheimer´s disease using a reverse translational approach
使用逆翻译方法重新利用治疗阿尔茨海默病的药物
- 批准号:
10295809 - 财政年份:2021
- 资助金额:
$ 330.67万 - 项目类别: